GLP‑1 medications for menopause weight gain: what the evidence shows

Introduction

Weight gain during perimenopause and menopause can feel different from earlier weight changes, especially when it concentrates around the abdomen. Some women are exploring whether semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) can help. The research is encouraging, though it comes with important considerations about what these medications can and cannot do during this stage of life.

Why menopause changes the weight equation

During the menopause transition, declining estrogen, disrupted sleep, increased stress, and shifts in insulin sensitivity can all make weight management harder. Many women notice more visceral fat even when their habits have not changed significantly.

GLP‑1 medications do not replace estrogen, directly treat hot flashes, or address every hormone-related symptom. What they can do is help with appetite, weight, blood sugar, and cardiometabolic risk factors when prescribed as part of a broader plan.

The evidence for midlife women is growing

A 2025 review in Current Opinion in Obstetrics and Gynecology concluded that GLP‑1 receptor agonists are among the most effective medications for weight loss and may be valuable for peri- and postmenopausal women, while noting that more population-specific data are needed.

A Weill Cornell post-hoc analysis of SURMOUNT trial data found that tirzepatide produced approximately 20 percent weight reduction in women regardless of whether they were premenopausal, perimenopausal, or postmenopausal. A 2026 scoping review in Cureus also found that GLP‑1 receptor agonists were associated with decreased central adiposity in menopausal women, though it called for larger studies on vasomotor symptoms, cardiovascular markers, and bone density.

Protein and strength training matter even more at midlife

Weight loss during menopause should protect muscle, not only lower the number on the scale. Lower appetite on a GLP‑1 can make it difficult to eat enough protein, and menopause is already a time when preserving lean mass is critical for metabolism, bone density, and daily function.

Prioritize protein at every meal, commit to resistance training, stay hydrated, and monitor fiber and sleep quality. If you are losing weight quickly, ask your clinician whether the pace and plan are appropriate.

Menopause symptoms still need their own care

Hot flashes, night sweats, vaginal dryness, sleep disruption, mood changes, and bone health all deserve attention from a provider who specializes in menopause care. GLP‑1 medications may indirectly help some symptoms through weight loss and improved metabolic health, but they are not a primary treatment for menopause.

If you use hormone therapy, blood pressure medication, diabetes medication, or thyroid medication, bring your full medication list to every appointment. Weight loss and lower intake can change how your other treatments work.

Track midlife progress with Shotsy

Shotsy helps you track weight, dose history, side effects, nutrition totals, hydration, and body measurements through Apple Health. When you reach your goal, maintenance mode helps you monitor stability. Those trends make it easier to protect muscle, spot side effects early, and have informed conversations with your clinician.

Conclusion

GLP‑1 medications may be helpful for women managing menopause-related weight gain, especially when appetite, insulin resistance, and central weight gain are part of the picture. They work best alongside protein, strength training, hydration, sleep support, and clinician oversight. Track more than weight so your progress stays healthy and sustainable through this transition.